Global BCG Vaccine Market Research Report 2020

BCG Vaccine is a vaccine primarily used against tuberculosis. Tuberculosis is a serious infection, which affects the lungs and sometimes other parts of the body, such as the bones, joints and kidneys. The bacille Calmette-Guérin (BCG) vaccine has existed for 80 years and is one of the most widely used of all current vaccines, reading >80%of neonates and infants in countries where it is part of the national childhood immunization programme.
The global average gross margin of BCG Vaccine is in an decreasing trend, from 71.59% in 2012 to 69.46% in 2017. With the situation of global economy, gross margin will be in decreasing trend in the following five years.

The type of BCG Vaccine includes Immune BCG and Therapy BCG. The proportion of Therapy BCG in 2016 is about 92.73%.

BCG Vaccine is widely used in Hospitals and Clinics. The most proportion of BCG Vaccine is sold in Hospitals and the market share in 2016 is about 74.14%, and the Hospitals have upstream trend.

North America is the largest supplier of BCG Vaccine, with a production market share nearly 32.58% in 2016. Europe is the second largest supplier of BCG Vaccine Media, enjoying production market share nearly 29.74% in 2016.

North America region is the largest consumption of BCG Vaccine, with a sales revenue market share nearly 36.40% in 2016. Europe is the second largest consumer of BCG Vaccine, enjoying sales revenue market share about 32.43% in 2016.

Market competition is not intense. Merck, Sanofi Pasteur, Japan BCG Lab, China National Biotec, Serum Institute of India, Intervax, GSBPL are the leaders of the industry, and they have been formed in the monopoly position in the industry.

The global BCG Vaccine market is valued at 336.4 million US$ in 2020 is expected to reach 494.8 million US$ by the end of 2026, growing at a CAGR of 5.6% during 2021-2026.
This report focuses on BCG Vaccine volume and value at the global level, regional level and company level. From a global perspective, this report represents overall BCG Vaccine market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan etc.
Market Segment Analysis
The research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type, the BCG Vaccine market is segmented into
Immune BCG
Therapy BCG

Segment by Application
Hospitals
Clinics
Others

Global BCG Vaccine Market: Regional Analysis
The BCG Vaccine market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026.
The key regions covered in the BCG Vaccine market report are:
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Global BCG Vaccine Market: Competitive Analysis
This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.
The major players in global BCG Vaccine market include:
Merck
Sanofi Pasteur
Japan BCG Lab
China National Biotec
Serum Institute of India
Intervax
GSBPL